|
RAPALOG THERAPY IN HERITABLE AND VIGABATRIN-INDUCED GABA METABOLIC DISORDERS |
1R01EY027476-01 |
GIBSON, K MICHAEL |
NEI |
2017 |
|
MECHANISMS OF SYNAPTIC SPECIFICITY IN VISUAL CIRCUITS |
3R01EY025627-02S1 |
TRIPLETT, JASON |
NEI |
2017 |
|
RAPALOG THERAPY IN HERITABLE AND VIGABATRIN-INDUCED GABA METABOLIC DISORDERS |
3R01EY027476-01S1 |
GIBSON, K MICHAEL |
NEI |
2017 |
|
TREATMENT OF A COMPLEX RETINAL DEGENERATIVE SYNDROME |
5R01EY011298-19 |
SHEFFIELD, VAL C. |
NEI |
2017 |
|
MECHANISMS OF ASSEMBLY OF PHOTORECEPTOR G PROTEIN COMPLEXES |
5R01EY012287-15 |
WILLARDSON, BARRY M |
NEI |
2017 |
|
IDENTIFICATION OF OPTIMUM SPECTACLE PRESCRIPTIONS FOR PATIENTS WITH DOWN SYNDROME |
5R01EY024590-04 |
ANDERSON, HEATHER ANNE |
NEI |
2017 |
|
RETINAL VERSUS CORTICAL CONTRIBUTIONS TO VISION LOSS IN ALBINISM |
5R01EY024969-03 |
CARROLL, JOSEPH |
NEI |
2017 |
|
MECHANISMS OF SYNAPTIC SPECIFICITY IN VISUAL CIRCUITS |
5R01EY025627-03 |
TRIPLETT, JASON |
NEI |
2017 |
|
ACTIVATION OF THE ANGIOPOIETIN-TIE2 PATHWAY TO TREAT OCULAR HYPERTENSION AND GLAUCOMA |
5R01EY025799-02 |
QUAGGIN, SUSAN E. |
NEI |
2017 |
|
INFANT APHAKIA TREATMENT STUDY-CHAIRMAN'S GRANT |
5UG1EY013272-16 |
LAMBERT, SCOTT R |
NEI |
2017 |